import{d as S,r as u,o as R,g as M,a as H,c as i,b as e,e as w,F as p,f as C,h as d,i as D,w as y,j as I,q as _,s as P,n as V,k as n,p as x,t as A,l as s,_ as B}from"./index-ffRJBDOO.js";const G={class:"min-h-screen pt-24 relative overflow-hidden"},F={class:"fixed inset-0 z-0 pointer-events-none overflow-hidden"},Y={class:"relative z-10 px-6 py-12"},U={class:"mx-auto max-w-7xl"},z={class:"space-y-24"},j={class:"relative grid lg:grid-cols-2 gap-8 p-8 lg:p-12"},W={class:"mb-4"},q={class:"mb-2 text-3xl font-bold text-white lg:text-4xl"},J={class:"mb-4 text-slate-500 flex items-center gap-2"},$={class:"mb-6 text-lg text-slate-400 leading-relaxed"},K={key:0,class:"mb-8 p-4 rounded-xl bg-slate-800/50 border border-slate-700/50"},Q={class:"text-xs text-slate-500 uppercase tracking-wider mb-2"},Z={class:"grid grid-cols-3 gap-4"},X={class:"text-xs text-slate-500"},e0={class:"relative"},t0={key:0,class:"rounded-2xl border border-slate-700/50 bg-slate-900/80 p-4 shadow-lg shadow-emerald-500/10"},r0={class:"flex flex-wrap gap-2 mb-4"},a0=["onClick"],o0={class:"overflow-x-auto"},l0={class:"w-full text-sm"},n0={class:"py-2 px-2 text-white font-medium text-xs"},A0={class:"inline-flex items-center gap-2"},i0={class:"w-5 h-5 rounded-full bg-emerald-500/20 text-emerald-400 text-xs flex items-center justify-center font-bold"},s0={class:"py-2 px-2 text-center"},c0={class:"text-emerald-400 font-mono font-bold"},d0={class:"py-2 px-2 text-center text-slate-300"},p0={class:"py-2 px-2 text-center"},C0={class:"px-2 py-0.5 rounded-full bg-emerald-500/10 text-emerald-400 text-xs font-medium"},T0={class:"mt-4 pt-3 border-t border-slate-700/50 flex items-center justify-between"},O0={class:"text-xs text-slate-500"},u0={key:0,class:"absolute inset-0 flex items-center justify-center bg-slate-900"},M0={class:"text-center"},m0=["onMouseenter","onMouseleave"],b0={class:"absolute bottom-4 left-4 right-4 flex items-center justify-between"},g0={class:"flex items-center gap-2"},v0=["onClick"],N0={class:"relative z-10 px-6 py-32"},x0={class:"mx-auto max-w-4xl"},h0={class:"relative rounded-3xl border border-slate-800 bg-gradient-to-br from-slate-900 via-slate-900/95 to-slate-900 p-12 text-center overflow-hidden"},f0={class:"relative"},E0={class:"flex flex-wrap justify-center gap-4"},L0=S({__name:"CaseStudiesPage",setup(k0){const m=u([]);let c=[];const h={glp1:`HEADER    PEPTIDE HORMONE                        01-JAN-25   XXXX
TITLE     GLP-1 AGONIST OPTIMIZED BY DEEPBIO SCIENTIFIC AI
ATOM      1  N   HIS A   1       0.000   0.000   0.000  1.00 20.00           N
ATOM      2  CA  HIS A   1       1.458   0.000   0.000  1.00 20.00           C
ATOM      3  C   HIS A   1       2.009   1.420   0.000  1.00 20.00           C
ATOM      4  O   HIS A   1       1.251   2.390   0.000  1.00 20.00           O
ATOM      5  CB  HIS A   1       1.990  -0.771   1.219  1.00 20.00           C
ATOM      6  N   ALA A   2       3.327   1.542   0.000  1.00 20.00           N
ATOM      7  CA  ALA A   2       3.974   2.851   0.000  1.00 20.00           C
ATOM      8  C   ALA A   2       5.481   2.726  -0.156  1.00 20.00           C
ATOM      9  O   ALA A   2       6.032   1.622  -0.266  1.00 20.00           O
ATOM     10  CB  ALA A   2       3.643   3.688   1.234  1.00 20.00           C
ATOM     11  N   GLU A   3       6.128   3.894  -0.156  1.00 20.00           N
ATOM     12  CA  GLU A   3       7.577   3.970  -0.306  1.00 20.00           C
ATOM     13  C   GLU A   3       8.094   5.394  -0.156  1.00 20.00           C
ATOM     14  O   GLU A   3       7.299   6.338  -0.054  1.00 20.00           O
ATOM     15  CB  GLU A   3       8.252   3.062  -1.338  1.00 20.00           C
ATOM     16  N   GLY A   4       9.410   5.545  -0.156  1.00 20.00           N
ATOM     17  CA  GLY A   4      10.024   6.867  -0.007  1.00 20.00           C
ATOM     18  C   GLY A   4      11.534   6.766   0.106  1.00 20.00           C
ATOM     19  O   GLY A   4      12.077   5.662   0.216  1.00 20.00           O
ATOM     20  N   THR A   5      12.193   7.925   0.095  1.00 20.00           N
ATOM     21  CA  THR A   5      13.641   7.973   0.201  1.00 20.00           C
ATOM     22  C   THR A   5      14.147   9.396   0.095  1.00 20.00           C
ATOM     23  O   THR A   5      13.343  10.329  -0.015  1.00 20.00           O
ATOM     24  CB  THR A   5      14.317   7.039   1.209  1.00 20.00           C
ATOM     25  N   PHE A   6      15.463   9.549   0.095  1.00 20.00           N
ATOM     26  CA  PHE A   6      16.066  10.874   0.000  1.00 20.00           C
ATOM     27  C   PHE A   6      17.576  10.753  -0.156  1.00 20.00           C
ATOM     28  O   PHE A   6      18.127   9.649  -0.266  1.00 20.00           O
ATOM     29  CB  PHE A   6      15.735  11.775   1.178  1.00 20.00           C
ATOM     30  N   THR A   7      18.224  11.921  -0.156  1.00 20.00           N
ATOM     31  CA  THR A   7      19.672  12.027  -0.301  1.00 20.00           C
ATOM     32  C   THR A   7      20.189  13.451  -0.156  1.00 20.00           C
ATOM     33  O   THR A   7      19.395  14.395  -0.054  1.00 20.00           O
ATOM     34  CB  THR A   7      20.347  11.093   1.209  1.00 20.00           C
ATOM     35  N   SER A   8      21.505  13.602  -0.156  1.00 20.00           N
ATOM     36  CA  SER A   8      22.119  14.924  -0.007  1.00 20.00           C
ATOM     37  C   SER A   8      23.629  14.823   0.106  1.00 20.00           C
ATOM     38  O   SER A   8      24.171  13.719   0.216  1.00 20.00           O
ATOM     39  CB  SER A   8      21.788  15.825   1.178  1.00 20.00           C
ATOM     40  N   ASP A   9      24.288  15.982   0.095  1.00 20.00           N
ATOM     41  CA  ASP A   9      25.736  16.088   0.201  1.00 20.00           C
ATOM     42  C   ASP A   9      26.242  17.510   0.095  1.00 20.00           C
ATOM     43  O   ASP A   9      25.438  18.444  -0.015  1.00 20.00           O
ATOM     44  CB  ASP A   9      26.412  15.180  -0.838  1.00 20.00           C
ATOM     45  N   VAL A  10      27.558  17.663   0.095  1.00 20.00           N
ATOM     46  CA  VAL A  10      28.161  18.988   0.000  1.00 20.00           C
ATOM     47  C   VAL A  10      29.671  18.867  -0.156  1.00 20.00           C
ATOM     48  O   VAL A  10      30.222  17.763  -0.266  1.00 20.00           O
ATOM     49  CB  VAL A  10      27.830  19.889   1.178  1.00 20.00           C
END`,proteinBinder:`HEADER    PROTEIN BINDER                         01-JAN-25   YYYY
TITLE     DE NOVO PROTEIN BINDER - ONCOLOGY TARGET
ATOM      1  N   MET A   1       0.000   0.000   0.000  1.00 15.00           N
ATOM      2  CA  MET A   1       1.458   0.000   0.000  1.00 15.00           C
ATOM      3  C   MET A   1       2.009   1.420   0.000  1.00 15.00           C
ATOM      4  O   MET A   1       1.251   2.390   0.000  1.00 15.00           O
ATOM      5  CB  MET A   1       1.990  -0.771   1.219  1.00 15.00           C
ATOM      6  N   ARG A   2       3.327   1.542   0.000  1.00 15.00           N
ATOM      7  CA  ARG A   2       3.974   2.851   0.000  1.00 15.00           C
ATOM      8  C   ARG A   2       5.481   2.726  -0.156  1.00 15.00           C
ATOM      9  O   ARG A   2       6.032   1.622  -0.266  1.00 15.00           O
ATOM     10  CB  ARG A   2       3.643   3.688   1.234  1.00 15.00           C
ATOM     11  N   TRP A   3       6.128   3.894  -0.156  1.00 15.00           N
ATOM     12  CA  TRP A   3       7.577   3.970  -0.306  1.00 15.00           C
ATOM     13  C   TRP A   3       8.094   5.394  -0.156  1.00 15.00           C
ATOM     14  O   TRP A   3       7.299   6.338  -0.054  1.00 15.00           O
ATOM     15  CB  TRP A   3       8.252   3.062   0.738  1.00 15.00           C
ATOM     16  N   LYS A   4       9.410   5.545  -0.156  1.00 15.00           N
ATOM     17  CA  LYS A   4      10.024   6.867  -0.007  1.00 15.00           C
ATOM     18  C   LYS A   4      11.534   6.766   0.106  1.00 15.00           C
ATOM     19  O   LYS A   4      12.077   5.662   0.216  1.00 15.00           O
ATOM     20  CB  LYS A   4      9.693   7.768   1.178  1.00 15.00           C
ATOM     21  N   LEU A   5      12.193   7.925   0.095  1.00 15.00           N
ATOM     22  CA  LEU A   5      13.641   7.973   0.201  1.00 15.00           C
ATOM     23  C   LEU A   5      14.147   9.396   0.095  1.00 15.00           C
ATOM     24  O   LEU A   5      13.343  10.329  -0.015  1.00 15.00           O
ATOM     25  CB  LEU A   5      14.317   7.039  -0.838  1.00 15.00           C
ATOM     26  N   ASN A   6      15.463   9.549   0.095  1.00 15.00           N
ATOM     27  CA  ASN A   6      16.066  10.874   0.000  1.00 15.00           C
ATOM     28  C   ASN A   6      17.576  10.753  -0.156  1.00 15.00           C
ATOM     29  O   ASN A   6      18.127   9.649  -0.266  1.00 15.00           O
ATOM     30  CB  ASN A   6      15.735  11.775   1.178  1.00 15.00           C
ATOM     31  N   GLN A   7      18.224  11.921  -0.156  1.00 15.00           N
ATOM     32  CA  GLN A   7      19.672  12.027  -0.301  1.00 15.00           C
ATOM     33  C   GLN A   7      20.189  13.451  -0.156  1.00 15.00           C
ATOM     34  O   GLN A   7      19.395  14.395  -0.054  1.00 15.00           O
ATOM     35  CB  GLN A   7      20.347  11.093   0.738  1.00 15.00           C
ATOM     36  N   CYS A   8      21.505  13.602  -0.156  1.00 15.00           N
ATOM     37  CA  CYS A   8      22.119  14.924  -0.007  1.00 15.00           C
ATOM     38  C   CYS A   8      23.629  14.823   0.106  1.00 15.00           C
ATOM     39  O   CYS A   8      24.171  13.719   0.216  1.00 15.00           O
ATOM     40  CB  CYS A   8      21.788  15.825   1.178  1.00 15.00           C
ATOM     41  SG  CYS A   8      22.350  15.150   2.800  1.00 15.00           S
END`,cmpNeu5Ac:`HEADER    SMALL MOLECULE - CMP-NEU5AC              01-JAN-25   CMNA
TITLE     CYTIDINE-5-MONOPHOSPHO-N-ACETYLNEURAMINIC ACID - COVID-19 INHIBITOR
HETATM    1  C1  CMN A   1       0.000   0.000   0.000  1.00 20.00           C
HETATM    2  C2  CMN A   1       1.400   0.000   0.500  1.00 20.00           C
HETATM    3  O2  CMN A   1       1.600   1.200   1.200  1.00 20.00           O
HETATM    4  C3  CMN A   1       2.400  -0.200  -0.600  1.00 20.00           C
HETATM    5  O3  CMN A   1       2.200  -1.400  -1.300  1.00 20.00           O
HETATM    6  C4  CMN A   1       3.800   0.000  -0.100  1.00 20.00           C
HETATM    7  O4  CMN A   1       4.000   1.400   0.100  1.00 20.00           O
HETATM    8  C5  CMN A   1       4.800  -0.600  -1.000  1.00 20.00           C
HETATM    9  N5  CMN A   1       4.600  -2.000  -1.200  1.00 20.00           N
HETATM   10  C10 CMN A   1       5.400  -2.800  -2.000  1.00 20.00           C
HETATM   11  O10 CMN A   1       6.400  -2.400  -2.600  1.00 20.00           O
HETATM   12  C11 CMN A   1       5.000  -4.200  -2.200  1.00 20.00           C
HETATM   13  C6  CMN A   1       6.200  -0.200  -0.500  1.00 20.00           C
HETATM   14  O6  CMN A   1       6.400   1.200  -0.300  1.00 20.00           O
HETATM   15  C7  CMN A   1       7.200  -0.800  -1.400  1.00 20.00           C
HETATM   16  O7  CMN A   1       7.000  -2.200  -1.600  1.00 20.00           O
HETATM   17  C8  CMN A   1       8.600  -0.400  -0.900  1.00 20.00           C
HETATM   18  O8  CMN A   1       8.800   1.000  -0.700  1.00 20.00           O
HETATM   19  C9  CMN A   1       9.600  -1.000  -1.800  1.00 20.00           C
HETATM   20  O9  CMN A   1       9.400  -2.400  -2.000  1.00 20.00           O
HETATM   21  P   CMN A   1      -1.200   0.600   0.800  1.00 20.00           P
HETATM   22  O1P CMN A   1      -1.000   2.000   1.200  1.00 20.00           O
HETATM   23  O2P CMN A   1      -2.400   0.400   0.000  1.00 20.00           O
HETATM   24  O3P CMN A   1      -1.400  -0.200   2.000  1.00 20.00           O
HETATM   25  C1R CMN A   1      -3.600   0.800  -0.600  1.00 20.00           C
HETATM   26  C2R CMN A   1      -4.600   1.600   0.200  1.00 20.00           C
HETATM   27  O2R CMN A   1      -4.400   3.000   0.000  1.00 20.00           O
HETATM   28  C3R CMN A   1      -6.000   1.200  -0.200  1.00 20.00           C
HETATM   29  O3R CMN A   1      -6.200  -0.200  -0.400  1.00 20.00           O
HETATM   30  C4R CMN A   1      -7.000   1.800   0.700  1.00 20.00           C
HETATM   31  O4R CMN A   1      -3.800   1.400  -1.800  1.00 20.00           O
HETATM   32  N1  CMN A   1      -8.400   1.400   0.300  1.00 20.00           N
HETATM   33  C2N CMN A   1      -9.400   2.200   0.800  1.00 20.00           C
HETATM   34  O2N CMN A   1      -9.200   3.200   1.500  1.00 20.00           O
HETATM   35  N3  CMN A   1     -10.600   1.800   0.400  1.00 20.00           N
HETATM   36  C4N CMN A   1     -10.800   0.600  -0.200  1.00 20.00           C
HETATM   37  N4  CMN A   1     -12.000   0.200  -0.600  1.00 20.00           N
HETATM   38  C5N CMN A   1      -9.800  -0.200  -0.600  1.00 20.00           C
HETATM   39  C6N CMN A   1      -8.600   0.200  -0.200  1.00 20.00           C
END`,mrnaVaccine:`HEADER    mRNA CONSTRUCT                          01-JAN-25   ZZZZ
TITLE     NEOANTIGEN PEPTIDE FOR CANCER VACCINE
ATOM      1  N   ALA A   1       0.000   0.000   0.000  1.00 25.00           N
ATOM      2  CA  ALA A   1       1.458   0.000   0.000  1.00 25.00           C
ATOM      3  C   ALA A   1       2.009   1.420   0.000  1.00 25.00           C
ATOM      4  O   ALA A   1       1.251   2.390   0.000  1.00 25.00           O
ATOM      5  CB  ALA A   1       1.990  -0.771   1.219  1.00 25.00           C
ATOM      6  N   ILE A   2       3.327   1.542   0.000  1.00 25.00           N
ATOM      7  CA  ILE A   2       3.974   2.851   0.000  1.00 25.00           C
ATOM      8  C   ILE A   2       5.481   2.726  -0.156  1.00 25.00           C
ATOM      9  O   ILE A   2       6.032   1.622  -0.266  1.00 25.00           O
ATOM     10  CB  ILE A   2       3.643   3.688   1.234  1.00 25.00           C
ATOM     11  N   TYR A   3       6.128   3.894  -0.156  1.00 25.00           N
ATOM     12  CA  TYR A   3       7.577   3.970  -0.306  1.00 25.00           C
ATOM     13  C   TYR A   3       8.094   5.394  -0.156  1.00 25.00           C
ATOM     14  O   TYR A   3       7.299   6.338  -0.054  1.00 25.00           O
ATOM     15  CB  TYR A   3       8.252   3.062   0.738  1.00 25.00           C
ATOM     16  N   PHE A   4       9.410   5.545  -0.156  1.00 25.00           N
ATOM     17  CA  PHE A   4      10.024   6.867  -0.007  1.00 25.00           C
ATOM     18  C   PHE A   4      11.534   6.766   0.106  1.00 25.00           C
ATOM     19  O   PHE A   4      12.077   5.662   0.216  1.00 25.00           O
ATOM     20  CB  PHE A   4       9.693   7.768   1.178  1.00 25.00           C
ATOM     21  N   PRO A   5      12.193   7.925   0.095  1.00 25.00           N
ATOM     22  CA  PRO A   5      13.641   7.973   0.201  1.00 25.00           C
ATOM     23  C   PRO A   5      14.147   9.396   0.095  1.00 25.00           C
ATOM     24  O   PRO A   5      13.343  10.329  -0.015  1.00 25.00           O
ATOM     25  CB  PRO A   5      14.317   7.039  -0.838  1.00 25.00           C
ATOM     26  N   GLU A   6      15.463   9.549   0.095  1.00 25.00           N
ATOM     27  CA  GLU A   6      16.066  10.874   0.000  1.00 25.00           C
ATOM     28  C   GLU A   6      17.576  10.753  -0.156  1.00 25.00           C
ATOM     29  O   GLU A   6      18.127   9.649  -0.266  1.00 25.00           O
ATOM     30  CB  GLU A   6      15.735  11.775   1.178  1.00 25.00           C
ATOM     31  N   LYS A   7      18.224  11.921  -0.156  1.00 25.00           N
ATOM     32  CA  LYS A   7      19.672  12.027  -0.301  1.00 25.00           C
ATOM     33  C   LYS A   7      20.189  13.451  -0.156  1.00 25.00           C
ATOM     34  O   LYS A   7      19.395  14.395  -0.054  1.00 25.00           O
ATOM     35  CB  LYS A   7      20.347  11.093   0.738  1.00 25.00           C
ATOM     36  N   VAL A   8      21.505  13.602  -0.156  1.00 25.00           N
ATOM     37  CA  VAL A   8      22.119  14.924  -0.007  1.00 25.00           C
ATOM     38  C   VAL A   8      23.629  14.823   0.106  1.00 25.00           C
ATOM     39  O   VAL A   8      24.171  13.719   0.216  1.00 25.00           O
ATOM     40  CB  VAL A   8      21.788  15.825   1.178  1.00 25.00           C
END`,gpr139Binder:`HEADER    GPR-139 SELECTIVE AGONIST                01-JAN-25   GPR1
TITLE     DE NOVO GPR-139 BINDER - ALPHAFOLD PREDICTED STRUCTURE
ATOM      1  N   VAL A   1     -32.179   9.477 -24.112  1.00 76.87           N
ATOM      2  CA  VAL A   1     -30.753   9.821 -24.348  1.00 86.25           C
ATOM      3  C   VAL A   1     -30.065  10.338 -23.080  1.00 86.86           C
ATOM      4  O   VAL A   1     -29.012   9.816 -22.734  1.00 85.12           O
ATOM      5  N   ALA A   2     -30.679  11.262 -22.331  1.00 84.53           N
ATOM      6  CA  ALA A   2     -30.104  11.788 -21.082  1.00 89.39           C
ATOM      7  C   ALA A   2     -29.867  10.718 -19.995  1.00 90.46           C
ATOM      8  O   ALA A   2     -28.827  10.712 -19.349  1.00 88.18           O
ATOM      9  N   PHE A   3     -30.783   9.751 -19.827  1.00 89.25           N
ATOM     10  CA  PHE A   3     -30.658   8.664 -18.852  1.00 88.58           C
ATOM     11  C   PHE A   3     -29.439   7.762 -19.106  1.00 88.87           C
ATOM     12  O   PHE A   3     -28.699   7.441 -18.178  1.00 88.47           O
ATOM     13  N   VAL A   4     -29.169   7.394 -20.356  1.00 89.25           N
ATOM     14  CA  VAL A   4     -28.019   6.553 -20.737  1.00 89.08           C
ATOM     15  C   VAL A   4     -26.691   7.289 -20.504  1.00 88.63           C
ATOM     16  O   VAL A   4     -25.731   6.677 -20.053  1.00 88.62           O
ATOM     17  N   LYS A   5     -26.657   8.608 -20.747  1.00 90.16           N
ATOM     18  CA  LYS A   5     -25.476   9.448 -20.510  1.00 87.33           C
ATOM     19  C   LYS A   5     -25.121   9.530 -19.015  1.00 86.26           C
ATOM     20  O   LYS A   5     -23.980   9.258 -18.662  1.00 88.96           O
ATOM     21  N   ASN A   6     -26.114   9.747 -18.141  1.00 92.49           N
ATOM     22  CA  ASN A   6     -25.914   9.749 -16.684  1.00 91.99           C
ATOM     23  C   ASN A   6     -25.444   8.386 -16.156  1.00 92.64           C
ATOM     24  O   ASN A   6     -24.608   8.324 -15.261  1.00 92.53           O
ATOM     25  N   TRP A   7     -25.943   7.271 -16.712  1.00 91.40           N
ATOM     26  CA  TRP A   7     -25.491   5.930 -16.338  1.00 90.44           C
ATOM     27  C   TRP A   7     -24.031   5.670 -16.725  1.00 90.93           C
ATOM     28  O   TRP A   7     -23.287   5.105 -15.929  1.00 91.92           O
ATOM     29  N   LEU A   8     -23.608   6.122 -17.914  1.00 92.86           N
ATOM     30  CA  LEU A   8     -22.215   6.013 -18.366  1.00 92.19           C
ATOM     31  C   LEU A   8     -21.271   6.864 -17.511  1.00 92.28           C
ATOM     32  O   LEU A   8     -20.201   6.388 -17.145  1.00 93.72           O
ATOM     33  N   GLU A   9     -21.665   8.082 -17.125  1.00 91.30           N
ATOM     34  CA  GLU A   9     -20.890   8.952 -16.234  1.00 91.30           C
ATOM     35  C   GLU A   9     -20.765   8.344 -14.826  1.00 91.52           C
ATOM     36  O   GLU A   9     -19.672   8.332 -14.264  1.00 92.30           O
ATOM     37  N   PHE A  10     -21.835   7.760 -14.287  1.00 93.67           N
ATOM     38  CA  PHE A  10     -21.808   7.052 -13.007  1.00 92.09           C
ATOM     39  C   PHE A  10     -20.880   5.829 -13.042  1.00 92.33           C
ATOM     40  O   PHE A  10     -20.072   5.646 -12.133  1.00 92.92           O
ATOM     41  N   LEU A  11     -20.946   5.010 -14.097  1.00 93.90           N
ATOM     42  CA  LEU A  11     -20.047   3.864 -14.288  1.00 92.40           C
ATOM     43  C   LEU A  11     -18.587   4.296 -14.392  1.00 92.29           C
ATOM     44  O   LEU A  11     -17.724   3.682 -13.760  1.00 93.90           O
ATOM     45  N   ALA A  12     -18.293   5.364 -15.134  1.00 92.66           N
ATOM     46  CA  ALA A  12     -16.942   5.897 -15.270  1.00 91.62           C
ATOM     47  C   ALA A  12     -16.394   6.407 -13.929  1.00 91.38           C
ATOM     48  O   ALA A  12     -15.260   6.076 -13.565  1.00 90.63           O
ATOM     49  N   GLN A  13     -17.195   7.121 -13.137  1.00 94.44           N
ATOM     50  CA  GLN A  13     -16.812   7.569 -11.798  1.00 93.77           C
ATOM     51  C   GLN A  13     -16.609   6.397 -10.835  1.00 93.93           C
ATOM     52  O   GLN A  13     -15.632   6.379 -10.089  1.00 93.82           O
ATOM     53  N   TRP A  14     -17.471   5.376 -10.872  1.00 95.37           N
ATOM     54  CA  TRP A  14     -17.350   4.193 -10.031  1.00 94.49           C
END`},b={"Spike-ACE2":[{drug:"Oseltamivir phosphate",pIC50:8.29,rankFDA:42,rankAntiviral:1},{drug:"Etravirine",pIC50:8.22,rankFDA:52,rankAntiviral:2},{drug:"Fosamprenavir calcium",pIC50:8.2,rankFDA:57,rankAntiviral:3},{drug:"Tipranavir",pIC50:7.94,rankFDA:108,rankAntiviral:4},{drug:"Elvitegravir",pIC50:7.88,rankFDA:141,rankAntiviral:5}],Helicase:[{drug:"Fosamprenavir calcium (FPV)",pIC50:7.51,rankFDA:21,rankAntiviral:1},{drug:"Simeprevir",pIC50:7.47,rankFDA:24,rankAntiviral:2},{drug:"Elvitegravir",pIC50:7.28,rankFDA:52,rankAntiviral:3},{drug:"Simeprevir sodium",pIC50:7.11,rankFDA:87,rankAntiviral:4},{drug:"Ritonavir",pIC50:7.01,rankFDA:120,rankAntiviral:6}],"3C-like":[{drug:"Fosamprenavir calcium",pIC50:7.72,rankFDA:5,rankAntiviral:1},{drug:"Elvitegravir",pIC50:7.25,rankFDA:29,rankAntiviral:2},{drug:"Tipranavir",pIC50:7.17,rankFDA:37,rankAntiviral:3},{drug:"Asunaprevir",pIC50:7.08,rankFDA:46,rankAntiviral:4},{drug:"Atazanavir sulfate",pIC50:6.92,rankFDA:68,rankAntiviral:6}],RdRp:[{drug:"Elvitegravir",pIC50:7.6,rankFDA:8,rankAntiviral:1},{drug:"Fosamprenavir calcium",pIC50:7.24,rankFDA:24,rankAntiviral:2},{drug:"Ritonavir",pIC50:6.96,rankFDA:53,rankAntiviral:3},{drug:"Asunaprevir",pIC50:6.9,rankFDA:66,rankAntiviral:4},{drug:"Simeprevir sodium",pIC50:6.87,rankFDA:71,rankAntiviral:5}]},g=[{id:1,title:"COVID-19 Drug Discovery: CMP-Neu5Ac",partner:"UCF Materials Science Lab",category:"Antiviral Discovery",sequence:"CC(=O)N[C@@H]1[C@@H](O)C[C@@](OC2O[C@H](COP(O)(=O)O)[C@@H](O)[C@H]2O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO",moleculeType:"smallMolecule",description:"Identified Cytidine-5'-monophospho-N-acetylneuraminic acid sodium salt (CMP-Neu5Ac) as a SARS-CoV-2 Spike Protein inhibitor through AI-driven molecular docking. Wet lab validated by UCF Materials Science Lab.",results:[{metric:"Validated",label:"UCF Wet Lab Confirmation"},{metric:"Spike RBD",label:"Target Binding Site"},{metric:"In Vitro",label:"Confirmed Inhibition"}],color:"purple",gradient:"from-purple-500 to-blue-500",pdbKey:"cmpNeu5Ac",viewerStyle:{stick:{colorscheme:"purpleCarbon",radius:.2},sphere:{colorscheme:"Jmol",scale:.25}}},{id:2,title:"COVID-19 Drug Repurposing: FDA-Approved Antivirals",partner:"AttentionSite-Augmented DeepDTA",category:"Drug Repurposing",sequence:"",moleculeType:"drugTable",description:"Top FDA-approved antiviral drugs predicted by AttentionSite-Augmented DeepDTA model to have highest affinity scores with 4 SARS-CoV-2 genome sequences. Identified candidates like Fosamprenavir, Elvitegravir, and Ritonavir as potential COVID-19 treatments.",results:[{metric:"3416",label:"FDA Drugs Screened"},{metric:"4",label:"Viral Targets"},{metric:"85",label:"Antivirals Ranked"}],color:"emerald",gradient:"from-emerald-500 to-teal-500",pdbKey:null,viewerStyle:null},{id:3,title:"GPR-139 Selective Agonist: De Novo Design",partner:"DeepBio Scientific AI Platform",category:"De Novo Peptide Design",sequence:"VAFVKNWLEFLAQWVASRLVNHQIGLQQELQIVAQAVLRYHQAETAKLSYTLAN",moleculeType:"peptide",description:"De novo designed GPR-139 selective agonist with 40% better predicted binding score than Dynorphin. Unlike RFDiffusion (21% structural similarity), our design achieves 0% similarity to existing proteins, enabling optimization to avoid off-target binding to opioid receptors (OPRM, OPRK, OPRD).",results:[{metric:"+40%",label:"Better Binding vs Dynorphin"},{metric:"0%",label:"Structural Similarity"},{metric:"Zero",label:"Off-Target Opioid Binding"}],color:"amber",gradient:"from-amber-500 to-orange-500",pdbKey:"gpr139Binder",viewerStyle:{cartoon:{color:"spectrum"},stick:{colorscheme:"orangeCarbon",radius:.15}}}];u(null);const v=u([!0,!0,!0]),T=u("Spike-ACE2");async function f(){const a=await _(()=>import("./3Dmol-DljS0b8b.js").then(r=>r._),[]);await P(),g.forEach((r,O)=>{const t=m.value[O];if(!t)return;const o=a.createViewer(t,{backgroundColor:"rgba(15, 23, 42, 0.9)",antialias:!0}),l=h[r.pdbKey];o.addModel(l,"pdb"),r.moleculeType==="smallMolecule"?(o.setStyle({},{stick:{colorscheme:"purpleCarbon",radius:.2},sphere:{colorscheme:"Jmol",scale:.3}}),o.addSurface(a.SurfaceType.VDW,{opacity:.25,color:"#a855f7"})):r.color==="cyan"?(o.setStyle({},{cartoon:{color:"spectrum"},stick:{colorscheme:"cyanCarbon",radius:.15}}),o.addSurface(a.SurfaceType.VDW,{opacity:.15,color:"#22d3ee"})):r.color==="purple"?(o.setStyle({},{cartoon:{color:"spectrum"},sphere:{colorscheme:"Jmol",scale:.25}}),o.addSurface(a.SurfaceType.VDW,{opacity:.15,color:"#a855f7"})):r.color==="amber"?(o.setStyle({},{cartoon:{color:"spectrum"},stick:{colorscheme:"orangeCarbon",radius:.15}}),o.addSurface(a.SurfaceType.VDW,{opacity:.15,color:"#f59e0b"})):(o.setStyle({},{cartoon:{color:"spectrum"},stick:{colorscheme:"orangeCarbon",radius:.15}}),o.addSurface(a.SurfaceType.VDW,{opacity:.15,color:"#ec4899"})),o.zoomTo(),o.render(),o.spin("y",.5),c.push(o),v.value[O]=!1})}function E(a){c[a]&&c[a].spin(!1)}function L(a){c[a]&&c[a].spin("y",.5)}function k(a){c[a]&&(c[a].zoomTo(),c[a].render())}return R(()=>{const a=document.querySelectorAll(".case-card");a.length>0&&M.fromTo(a,{opacity:0,y:50,scale:.95},{opacity:1,y:0,scale:1,stagger:.2,duration:.8,ease:"power3.out",delay:.3}),M.fromTo(".hero-title",{opacity:0,y:30},{opacity:1,y:0,duration:1,ease:"power3.out"}),M.fromTo(".hero-badge",{opacity:0,scale:.8},{opacity:1,scale:1,duration:.6,ease:"back.out(1.7)",delay:.2}),M.to(".floating-particle",{y:-20,duration:2,repeat:-1,yoyo:!0,ease:"sine.inOut",stagger:.2}),f()}),H(()=>{c.forEach(a=>{a&&a.spin(!1)}),c=[]}),(a,r)=>{const O=I("router-link");return s(),i("div",G,[e("div",F,[r[0]||(r[0]=e("div",{class:"absolute top-1/4 left-1/4 w-96 h-96 bg-cyan-500/10 rounded-full blur-3xl animate-pulse"},null,-1)),r[1]||(r[1]=e("div",{class:"absolute bottom-1/4 right-1/4 w-96 h-96 bg-purple-500/10 rounded-full blur-3xl animate-pulse",style:{"animation-delay":"1s"}},null,-1)),r[2]||(r[2]=e("div",{class:"absolute top-1/2 left-1/2 w-64 h-64 bg-blue-500/10 rounded-full blur-3xl animate-pulse",style:{"animation-delay":"2s"}},null,-1)),r[3]||(r[3]=e("div",{class:"absolute inset-0 bg-[linear-gradient(rgba(34,211,238,0.03)_1px,transparent_1px),linear-gradient(90deg,rgba(34,211,238,0.03)_1px,transparent_1px)] bg-[size:60px_60px]"},null,-1)),(s(),i(p,null,C(20,t=>e("div",{key:t,class:n(["floating-particle absolute w-1 h-1 rounded-full",[t%3===0?"bg-cyan-400":t%3===1?"bg-purple-400":"bg-blue-400"]]),style:V({left:`${Math.random()*100}%`,top:`${Math.random()*100}%`,opacity:.3+Math.random()*.4,animationDelay:`${Math.random()*2}s`})},null,6)),64))]),r[15]||(r[15]=w('<section class="relative z-10 px-6 py-20" data-v-96991858><div class="mx-auto max-w-6xl text-center" data-v-96991858><div class="hero-badge mb-6 inline-flex items-center gap-2 rounded-full border border-amber-500/30 bg-amber-500/10 px-5 py-2 backdrop-blur-sm" data-v-96991858><span class="relative flex h-2 w-2" data-v-96991858><span class="absolute inline-flex h-full w-full animate-ping rounded-full bg-amber-400 opacity-75" data-v-96991858></span><span class="relative inline-flex h-2 w-2 rounded-full bg-amber-500" data-v-96991858></span></span><span class="text-sm font-medium text-amber-300" data-v-96991858>Case Studies</span></div><h1 class="hero-title mb-6 text-5xl font-bold text-white md:text-7xl" data-v-96991858> Proven <span class="bg-gradient-to-r from-amber-400 via-orange-400 to-blue-400 bg-clip-text text-transparent animate-gradient" data-v-96991858>Results</span></h1><p class="hero-title mx-auto max-w-3xl text-xl text-slate-400 leading-relaxed" data-v-96991858> Explore our <span class="text-cyan-400" data-v-96991858>AI-designed therapeutics</span> with interactive 3D molecular viewers. Rotate, zoom, and examine the structures that are advancing medicine. </p><div class="mt-8 flex items-center justify-center gap-2 text-sm text-slate-500" data-v-96991858><svg class="w-5 h-5 animate-bounce" fill="none" stroke="currentColor" viewBox="0 0 24 24" data-v-96991858><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M15 15l-2 5L9 9l11 4-5 2zm0 0l5 5M7.188 2.239l.777 2.897M5.136 7.965l-2.898-.777M13.95 4.05l-2.122 2.122m-5.657 5.656l-2.12 2.122" data-v-96991858></path></svg><span data-v-96991858>Click and drag on molecules to rotate â€¢ Scroll to zoom</span></div></div></section>',1)),e("section",Y,[e("div",U,[e("div",z,[(s(),i(p,null,C(g,(t,o)=>e("div",{key:t.id,class:"case-card group"},[e("div",{class:n(["relative rounded-3xl border border-slate-800/50 bg-gradient-to-br from-slate-900/90 to-slate-900/50 p-1 backdrop-blur-xl overflow-hidden transition-all duration-500 hover:border-slate-700/50",[t.color==="cyan"?"hover:shadow-2xl hover:shadow-cyan-500/20":"",t.color==="purple"?"hover:shadow-2xl hover:shadow-purple-500/20":"",t.color==="pink"?"hover:shadow-2xl hover:shadow-blue-500/20":"",t.color==="emerald"?"hover:shadow-2xl hover:shadow-emerald-500/20":"",t.color==="amber"?"hover:shadow-2xl hover:shadow-amber-500/20":""]])},[e("div",{class:n(["absolute inset-0 opacity-0 transition-opacity duration-500 group-hover:opacity-100",[t.color==="cyan"?"bg-gradient-to-br from-cyan-500/10 via-transparent to-transparent":"",t.color==="purple"?"bg-gradient-to-br from-purple-500/10 via-transparent to-transparent":"",t.color==="pink"?"bg-gradient-to-br from-blue-500/10 via-transparent to-transparent":"",t.color==="emerald"?"bg-gradient-to-br from-emerald-500/10 via-transparent to-transparent":"",t.color==="amber"?"bg-gradient-to-br from-amber-500/10 via-transparent to-transparent":""]])},null,2),e("div",j,[e("div",{class:n(o%2===1?"lg:order-2":"")},[e("div",W,[e("span",{class:n(["rounded-full px-4 py-1.5 text-xs font-semibold tracking-wide uppercase ring-1",[t.color==="cyan"?"bg-cyan-500/10 text-cyan-400 ring-cyan-500/30":"",t.color==="purple"?"bg-purple-500/10 text-purple-400 ring-purple-500/30":"",t.color==="pink"?"bg-blue-500/10 text-blue-400 ring-blue-500/30":"",t.color==="emerald"?"bg-emerald-500/10 text-emerald-400 ring-emerald-500/30":"",t.color==="amber"?"bg-amber-500/10 text-amber-400 ring-amber-500/30":""]])},A(t.category),3)]),e("h2",q,A(t.title),1),e("p",J,[r[4]||(r[4]=e("svg",{class:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24"},[e("path",{"stroke-linecap":"round","stroke-linejoin":"round","stroke-width":"2",d:"M19 21V5a2 2 0 00-2-2H7a2 2 0 00-2 2v16m14 0h2m-2 0h-5m-9 0H3m2 0h5M9 7h1m-1 4h1m4-4h1m-1 4h1m-5 10v-5a1 1 0 011-1h2a1 1 0 011 1v5m-4 0h4"})],-1)),d(" "+A(t.partner),1)]),e("p",$,A(t.description),1),t.moleculeType!=="drugTable"?(s(),i("div",K,[e("p",Q,A(t.moleculeType==="smallMolecule"?"SMILES Structure":"Peptide Sequence"),1),e("p",{class:n(["font-mono text-sm tracking-wider break-all",[t.color==="cyan"?"text-cyan-400":"",t.color==="purple"?"text-purple-400":"",t.color==="pink"?"text-blue-400":"",t.color==="emerald"?"text-emerald-400":"",t.color==="amber"?"text-amber-400":""]])},A(t.sequence),3)])):x("",!0),e("div",Z,[(s(!0),i(p,null,C(t.results,l=>(s(),i("div",{key:l.label,class:n(["text-center p-4 rounded-xl bg-slate-800/30 border border-slate-700/30 transition-all duration-300 hover:scale-105",[t.color==="cyan"?"hover:border-cyan-500/30":"",t.color==="purple"?"hover:border-purple-500/30":"",t.color==="pink"?"hover:border-blue-500/30":"",t.color==="emerald"?"hover:border-emerald-500/30":"",t.color==="amber"?"hover:border-amber-500/30":""]])},[e("div",{class:n(["text-2xl lg:text-3xl font-bold mb-1",[t.color==="cyan"?"text-cyan-400":"",t.color==="purple"?"text-purple-400":"",t.color==="pink"?"text-blue-400":"",t.color==="emerald"?"text-emerald-400":"",t.color==="amber"?"text-amber-400":""]])},A(l.metric),3),e("div",X,A(l.label),1)],2))),128))])],2),e("div",{class:n(o%2===1?"lg:order-1":"")},[e("div",e0,[t.moleculeType==="drugTable"?(s(),i("div",t0,[e("div",r0,[(s(!0),i(p,null,C(Object.keys(b),l=>(s(),i("button",{key:l,onClick:N=>T.value=l,class:n(["px-3 py-1.5 rounded-lg text-xs font-medium transition-all",T.value===l?"bg-emerald-500/20 text-emerald-300 ring-1 ring-emerald-500/50":"bg-slate-800/50 text-slate-400 hover:bg-slate-700/50"])},A(l),11,a0))),128))]),e("div",o0,[e("table",l0,[r[5]||(r[5]=e("thead",null,[e("tr",{class:"border-b border-slate-700/50"},[e("th",{class:"text-left py-2 px-2 text-slate-400 font-medium text-xs"},"Drug Name"),e("th",{class:"text-center py-2 px-2 text-slate-400 font-medium text-xs"},"pIC50"),e("th",{class:"text-center py-2 px-2 text-slate-400 font-medium text-xs"},"FDA Rank"),e("th",{class:"text-center py-2 px-2 text-slate-400 font-medium text-xs"},"Antiviral Rank")])],-1)),e("tbody",null,[(s(!0),i(p,null,C(b[T.value],(l,N)=>(s(),i("tr",{key:l.drug,class:"border-b border-slate-800/50 hover:bg-slate-800/30 transition-colors"},[e("td",n0,[e("span",A0,[e("span",i0,A(N+1),1),d(" "+A(l.drug),1)])]),e("td",s0,[e("span",c0,A(l.pIC50.toFixed(2)),1)]),e("td",d0,"#"+A(l.rankFDA),1),e("td",p0,[e("span",C0,"#"+A(l.rankAntiviral),1)])]))),128))])])]),e("div",T0,[e("p",O0,"Top 5 candidates for "+A(T.value)+" target",1),r[6]||(r[6]=e("div",{class:"px-3 py-1.5 rounded-lg text-xs font-medium bg-emerald-500/20 text-emerald-300"},[e("span",{class:"inline-block w-2 h-2 rounded-full animate-pulse mr-2 bg-emerald-400"}),d(" AI Predictions ")],-1))])])):(s(),i("div",{key:1,class:n(["relative aspect-square rounded-2xl overflow-hidden border border-slate-700/50 bg-slate-900/80",[t.color==="cyan"?"shadow-lg shadow-cyan-500/10":"",t.color==="purple"?"shadow-lg shadow-purple-500/10":"",t.color==="pink"?"shadow-lg shadow-blue-500/10":"",t.color==="amber"?"shadow-lg shadow-amber-500/10":""]])},[v.value[o]?(s(),i("div",u0,[e("div",M0,[e("div",{class:n(["w-12 h-12 mx-auto mb-4 border-4 border-slate-700 rounded-full animate-spin",[t.color==="cyan"?"border-t-cyan-500":"",t.color==="purple"?"border-t-purple-500":"",t.color==="pink"?"border-t-blue-500":"",t.color==="amber"?"border-t-amber-500":""]])},null,2),r[7]||(r[7]=e("p",{class:"text-sm text-slate-500"},"Loading 3D structure...",-1))])])):x("",!0),e("div",{ref_for:!0,ref:l=>m.value[o]=l,class:"w-full h-full min-h-[350px] lg:min-h-[450px]",onMouseenter:l=>E(o),onMouseleave:l=>L(o)},null,40,m0),e("div",b0,[e("div",g0,[e("button",{onClick:l=>k(o),class:"px-3 py-1.5 rounded-lg text-xs font-medium bg-slate-800/80 text-slate-300 hover:bg-slate-700 transition-colors backdrop-blur-sm"},r[8]||(r[8]=[e("svg",{class:"w-4 h-4 inline-block mr-1",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24"},[e("path",{"stroke-linecap":"round","stroke-linejoin":"round","stroke-width":"2",d:"M4 4v5h.582m15.356 2A8.001 8.001 0 004.582 9m0 0H9m11 11v-5h-.581m0 0a8.003 8.003 0 01-15.357-2m15.357 2H15"})],-1),d(" Reset ",-1)]),8,v0)]),e("div",{class:n(["px-3 py-1.5 rounded-lg text-xs font-medium backdrop-blur-sm",[t.color==="cyan"?"bg-cyan-500/20 text-cyan-300":"",t.color==="purple"?"bg-purple-500/20 text-purple-300":"",t.color==="pink"?"bg-blue-500/20 text-blue-300":"",t.color==="amber"?"bg-amber-500/20 text-amber-300":""]])},[e("span",{class:n(["inline-block w-2 h-2 rounded-full animate-pulse mr-2",[t.color==="cyan"?"bg-cyan-400":"",t.color==="purple"?"bg-purple-400":"",t.color==="pink"?"bg-blue-400":"",t.color==="amber"?"bg-amber-400":""]])},null,2),r[9]||(r[9]=d(" Interactive 3D ",-1))],2)])],2)),e("div",{class:n(["absolute -top-4 -right-4 w-24 h-24 rounded-full blur-2xl opacity-30",[t.color==="cyan"?"bg-cyan-500":"",t.color==="purple"?"bg-purple-500":"",t.color==="pink"?"bg-blue-500":"",t.color==="emerald"?"bg-emerald-500":"",t.color==="amber"?"bg-amber-500":""]])},null,2),e("div",{class:n(["absolute -bottom-4 -left-4 w-32 h-32 rounded-full blur-3xl opacity-20",[t.color==="cyan"?"bg-blue-500":"",t.color==="purple"?"bg-blue-500":"",t.color==="pink"?"bg-orange-500":"",t.color==="emerald"?"bg-teal-500":"",t.color==="amber"?"bg-orange-500":""]])},null,2)])],2)])],2)])),64))])])]),e("section",N0,[e("div",x0,[e("div",h0,[r[13]||(r[13]=e("div",{class:"absolute inset-0 bg-gradient-to-r from-cyan-500/5 via-purple-500/5 to-blue-500/5"},null,-1)),r[14]||(r[14]=e("div",{class:"absolute top-0 left-1/2 -translate-x-1/2 w-96 h-96 bg-gradient-to-b from-cyan-500/20 to-transparent rounded-full blur-3xl"},null,-1)),e("div",f0,[r[11]||(r[11]=e("h2",{class:"mb-6 text-3xl font-bold text-white md:text-4xl"},[d(" Ready to Start Your "),e("span",{class:"bg-gradient-to-r from-cyan-400 via-purple-400 to-blue-400 bg-clip-text text-transparent"},"Success Story"),d("? ")],-1)),r[12]||(r[12]=e("p",{class:"mb-8 text-lg text-slate-400 max-w-2xl mx-auto"}," Join leading pharmaceutical and biotech companies using DeepBio Scientific to accelerate therapeutic discovery with AI-powered molecular design. ",-1)),e("div",E0,[D(O,{to:"/contact",class:"group relative overflow-hidden rounded-full bg-gradient-to-r from-cyan-500 to-purple-600 px-8 py-4 font-semibold text-white shadow-lg shadow-cyan-500/30 transition-all hover:shadow-cyan-500/50"},{default:y(()=>r[10]||(r[10]=[e("span",{class:"relative z-10"},"Start a Partnership",-1),e("div",{class:"absolute inset-0 bg-gradient-to-r from-purple-600 to-blue-600 opacity-0 transition-opacity group-hover:opacity-100"},null,-1)])),_:1,__:[10]})])])])])])])}}}),R0=B(L0,[["__scopeId","data-v-96991858"]]);export{R0 as default};
